Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Defence Therapeutics ( (TSE:DTC) ).
Defence Therapeutics has expanded its long-standing collaboration with Canadian Nuclear Laboratories to accelerate development of its Accum®-enhanced radiopharmaceutical pipeline. Building on progress in a lead radio-immunoconjugate program that is nearing candidate selection and preparation for first-in-human clinical studies, the partners will now initiate multiple additional radioisotope programs using Defence’s intracellular delivery technology. The move elevates radiopharmaceuticals to one of Defence’s top development priorities alongside its ADC program, strengthens its position in targeted cancer therapies, and is intended to speed the translation of its proprietary platform into the clinic, with potential implications for more potent, less toxic first-line cancer treatments.
The most recent analyst rating on (TSE:DTC) stock is a Hold with a C$0.60 price target. To see the full list of analyst forecasts on Defence Therapeutics stock, see the TSE:DTC Stock Forecast page.
Spark’s Take on TSE:DTC Stock
According to Spark, TipRanks’ AI Analyst, TSE:DTC is a Neutral.
The score is held down primarily by very weak financial performance (no revenue, cash burn, negative equity) and bearish technical signals (below key moving averages with negative MACD). Positive corporate developments around the Accum®/ADC platform and strategic governance/financing actions provide some support but are not enough to outweigh the current financial and trend risks.
To see Spark’s full report on TSE:DTC stock, click here.
More about Defence Therapeutics
Defence Therapeutics is a publicly traded biotechnology company specializing in precision intracellular drug delivery for cancer treatment. Leveraging its proprietary Accum® platform, the company focuses on enhancing the potency and safety of antibody-drug conjugates (ADCs), radiopharmaceuticals and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced cancer therapies through collaborations with pharmaceutical and biotech partners.
Average Trading Volume: 66,751
Technical Sentiment Signal: Sell
Current Market Cap: C$35.02M
For a thorough assessment of DTC stock, go to TipRanks’ Stock Analysis page.